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342 IBW< 85% in the ﬁrst year of life and pulmonary manifestations
at 6 years old, in patients with cystic ﬁbrosis
S. Mosescu1. 1pediatrics, Central Children’s Hospital, Bucharest, Romania
Objectives: 2 groups of cystic ﬁbrosis(CF) patients (diagnosed <6 months old:
Group A-patients with IBW< 85% at12 months and Group B-patients with
IBW> 90% at 12 months old, are compared at the age of 6 years, regarding
pulmonary manifestations: bronchiectasis, respiratory chronic infections and pul-
monary function tests (PFT).
Methods and Material: retrospective study on 10 patients with CF: Group A: 6 pa-
tients with IBW< 85% at 12 months old and Group B: 4 patients with IBW> 90%.
They have been followed in our Clinic, on the same treatment and follow up
criteria. At the age of 6 years we compare the 2 Groups: presence of bronchiectasis
(CT scan), presence of respiratory chronic infection with Staphylococcus aureus
and Pseudomonas aeruginosa and we determine PFT.
Results: All patients(6/6) from Group A developed bronchiectasis comparing
with just 1 (1/4) from the Group B. None of the patients with IBW> 90% had
Ps. aeruginosa lung infection comparing with 50% (3/6) from the patients with
IBW< 85%. Lung function values are worse in Group A comparing with Group B.
Conclusions: IBW< 85% at 12 months old is a bad prognosis factor for respiratory
manifestations at 6 years old, in patients with CF. Bronchiectasis develop earlier
in patients with IBW< 85% at 1 year old. Lung function is worse in patients
that had IBW< 85% and is much more deteriorated in those with respiratory
chronic infections. Lung function tests at 6 years are in normal ranges in those
with bronchiectasis and without respiratory chronic infection. We consider that
bronchiectasis is much more related to nutritional status and lung function tests are
much related to respiratory chronic infection. Efforts should be done in the ﬁrst
year of life to improve nutritional status and restore to normal growth parameters
and to prevent and treat respiratory chronic infections.
343 The effects of lung transplantation on the nutritional status of
patients with cystic ﬁbrosis
M. Caraher1, S.J. Doe1, A. Anderson1, K. Heslop1, S. Johnston1, K. Stavers1,
S.J. Bourke1. 1Adult Cystic Fibrosis Centre, Royal Victoria Inﬁrmary, Newcastle
upon Tyne, United Kingdom
Introduction: Many patients with advanced CF are malnourished due to the in-
creased energy demands of lung infection and reduced nutritional intake associated
with anorexia and malabsorption. Lung transplantation removes the catabolic effect
of infected lungs but patients still have pancreatic insufﬁciency. We studied the
weight changes occurring in our patients pre and post transplant.
Results: Twelve patients in our CF Centre had their nutritional status assessed for
one year before and after transplantation. Their mean age at transplant was 29.3
(range 19−42) years and mean waiting time to transplant was 16.6 (range 8−63)
months. Their mean body mass index (BMI) was generally maintained by intensive
nutritional support pre transplant. With the dramatic improvement in lung function
most patients gained weight in the year post transplant, but only 4 (33%) have
achieved a normal BMI (22−23 kg/m2).
Conclusion: With improved lung function and removal of the catabolic effect of
infected lungs, BMI generally improves but patients still have nutritional deﬁcits
and require ongoing dietetic support.
BMI 1 year before Transplant 20.0 (17.6−22.4)
BMI at Transplant 19.6 (17.3−24.3)
BMI 1 year post transplant 22.0 (16.8−29.6)
FEV1 (L) pre Transplant 0.88 (0.5−1.3)
FEV1 (L), 1 year post Transplant 3.38 (1.61−4.94)
345 Supplement Snack-Bar: a new approach to improve compliance
with oral supplements in children with CF
C. Smith1, J. Lenton1, C. Warde1, P. Seddon1. 1Cystic Fibrosis Clinic, Royal
Alexandra Children’s Hospital, Brighton, United Kingdom
Optimal nutrition during childhood in CF is associated with improved survival.
However, studies of interventions with oral supplements have shown conﬂicting
results, and it has been suggested that this may be partly because of poor
compliance. Contributing factors to poor compliance are prescribing of untried
supplements and poor understanding of varieties available: children’s tastes are
individual and unpredictable.
To address these issues and improve compliance, we introduced a novel “Supple-
ment snack-bar” into our paediatric CF clinic for an experimental 9-month period,
and assessed parents’ and children’s responses by anonymised questionnaires. At
each clinic we invited manufacturers to present full-range tasting sessions of their
products. Any child felt clinically to require oral supplements was able to browse
the range and identify a preferred product before prescribing. Each child over
7 years of age was given one questionnaire to complete and one questionnaire for
the accompanying parent.
11 child/parent pairs of questionnares were distributed; 11 child and 9 parent
questionnaires were returned. 55% of parents and 36% of children found the
sessions “very helpful”, while a further 44% of parents and 55% of children found
them “fairly helpful”. When asked if there had been any effect on subsequent
compliance with supplements, 11% of parents and 45% of children felt it had made
a “big difference”, while a further 89% of parents and 36% of children felt it had
made “some difference” – no parents or children rated “no difference”.
Our results suggest this type of intervention is popular, and may have the potential
to improve compliance with nutritional supplements, but a further study using more
objective measures of compliance is needed.
346* The experience of using megestrol acetate (MA) in a large UK
adult CF centre
J. Barrett1, B. Ahitan1, E.F. Nash1, J. Whitehouse1, D. Honeybourne1. 1West
Midlands Adult Cystic Fibrosis Centre, Birmingham, United Kingdom
Background: Cystic Fibrosis (CF) leads to poor nutritional status in many patients.
Appetite stimulants such as MA may be used with conventional nutritional treat-
ments to improve appetite and aid weight gain. We report our experience of using
MA in CF adults.
Methods:We identiﬁed all patients treated with MA from 2003–2008. We recorded
gender, age, CF-related diabetes (CFRD), height, weight, body mass index (BMI)
and lung function before starting MA. We recorded duration of treatment, dose,
reason for stopping MA and side effects. Nutritional interventions while receiving
MA were documented. Weight, BMI and lung function were recorded on stopping
MA, as well as 3 and 6 months afterwards.
Results: 25 patients were included (12 male). 2 were post-lung transplantation
and 2 were post-liver transplantation. Median age at the time of starting MA
was 27.4 yrs (range 18.1−50.8 yrs). 4 patients had CFRD. Median starting dose
of MA was 320mg (range 160–480mg) and median duration of therapy was
83 days (range 10–756 days). Median weight gain during the treatment period was
4.9kg (range −0.8−14.7kg). There was a signiﬁcant correlation between duration of
treatment and weight change over the treatment period (R=0.65, p< 0.001). Weight
gain was generally maintained 3 months after discontinuing MA (median 3.6kg
weight gain vs. baseline) and at 6 months (median 3.8kg weight gain vs. baseline).
FEV1% predicted was signiﬁcantly increased comparing pre and post MA treatment
(p< 0.03).
Conclusions: Adult CF patients receiving MA in addition to other nutritional
supplementation gain weight and improve lung function. This weight gain is
sustained up to 6 months after discontinuing MA. MA is generally well tolerated
with few patients reporting adverse events.
